Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Lower FEV1 in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV1, total IgE levels, and TSLP genotypes

Authors Hironori Masuko, Tohru Sakamoto, Shiko Kaneko, et al

Published 2 March 2011 Volume 2011:6 Pages 181—189

DOI https://doi.org/10.2147/COPD.S16383

Review by Single-blind

Peer reviewer comments 3

Hironori Masuko1, Tohru Sakamoto1, Yoshiko Kaneko1, Hiroaki Iijima2, Takashi Naito2, Emiko Noguchi3, Tomomitsu Hirota4, Mayumi Tamari4, Nobuyuki Hizawa1
1Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan; 2Tsukuba Medical Center, Ibaraki, Japan; 3Department of Medical Genetics, Majors of Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan; 4Laboratory for Respiratory Diseases, Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan

Abstract: Few studies have investigated the significance of decreased FEV1 in non-COPD, nonasthmatic healthy subjects. We hypothesized that a lower FEV1 in these subjects is a potential marker of an increased susceptibility to obstructive lung disease such as asthma and COPD. This was a cross-sectional analysis of 1505 Japanese adults. We divided the population of healthy adults with no respiratory diseases whose FEV1/FVC ratio was ≥70% (n = 1369) into 2 groups according to their prebronchodilator FEV1 (% predicted) measurements:<80% (n = 217) and ≥80% (n = 1152). We compared clinical data – including gender, age, smoking habits, total IgE levels, and annual decline of FEV1 – between these 2 groups. In addition, as our group recently found that TSLP variants are associated with asthma and reduced lung function, we assessed whether TSLP single nucleotide polymorphisms (SNPs) were associated with baseline lung function in non-COPD, nonasthmatic healthy subjects (n = 1368). Although about half of the subjects with lower FEV1 had never smoked, smoking was the main risk factor for the decreased FEV1 in non-COPD, nonasthmatic subjects. However, the subjects with lower FEV1 had a significantly higher annual decline in FEV1 independent of smoking status. Airflow obstruction was associated with increased levels of total serum IgE (P = 0.029) and with 2 functional TSLP SNPs (corrected P = 0.027–0.058 for FEV1% predicted, corrected P = 0.015–0.033 for FEV1/FVC). This study highlights the importance of early recognition of a decreased FEV1 in healthy subjects without evident pulmonary diseases because it predicts a rapid decline in FEV1 irrespective of smoking status. Our series of studies identified TSLP variants as a potential susceptibility locus to asthma and to lower lung function in non-COPD, nonasthmatic healthy subjects, which may support the contention that genetic determinants of lung function influence susceptibility to asthma.

Keywords: airflow obstruction, asthma, chronic obstructive pulmonary disease, pulmonary function test, thymic stromal lymphopoietin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

The search for common pathways underlying asthma and COPD

Kaneko Y, Yatagai Y, Yamada H, Iijima H, Masuko H, Sakamoto T, Hizawa N

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:65-78

Published Date: 25 January 2013

Readers of this article also read:

Cytotoxicity and physicochemical characterization of iron–manganese-doped sulfated zirconia nanoparticles [Corrigendum]

Al-Fahdawi MQ, Rasedee A, Al-Qubaisi MS, Alhassan FH, Rosli R, El Zowalaty ME, Naadja SE, Webster TJ, Taufiq-Yap YH

International Journal of Nanomedicine 2015, 10:6657-6658

Published Date: 28 October 2015

Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design

Fard Masoumi HR, Basri M, Sarah Samiun W, Izadiyan Z, Lim CJ

International Journal of Nanomedicine 2015, 10:6469-6476

Published Date: 13 October 2015

Identification of genetic variants in the TNF promoter associated with COPD secondary to tobacco smoking and its severity

Reséndiz-Hernández JM, Sansores RH, Hernández-Zenteno RJ, Vargas-Alarcón G, Colín-Barenque L, Velázquez-Uncal M, Camarena A, Ramírez-Venegas A, Falfán-Valencia R

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1241-1251

Published Date: 29 June 2015

Pharmacokinetics of quercetin-loaded nanodroplets with ultrasound activation and their use for bioimaging

Chang LW, Hou ML, Hung SH, Lin LC, Tsai TH

International Journal of Nanomedicine 2015, 10:3031-3042

Published Date: 17 April 2015

Home-based pulmonary rehabilitation improves clinical features and systemic inflammation in chronic obstructive pulmonary disease patients

Nascimento ESP, Sampaio LMM, Peixoto-Souza FS, Dias FD, Gomes ELFD, Greiffo FR, Ligeiro de Oliveira AP, Stirbulov R, Vieira RP, Costa D

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:645-653

Published Date: 23 March 2015

EGLN2 and RNF150 genetic variants are associated with chronic obstructive pulmonary disease risk in the Chinese population

Ding YP, Niu H, Yang H, Sun P, Chen Y, Duan ML, Xu DC, Xu JX, Jin TB

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:145-151

Published Date: 13 January 2015

Development of nanofluorapatite polymer-based composite for bioactive orthopedic implants and prostheses

Hu G, Wang H, Yao X, Bi D, Zhu G, Tang S, Wei J, Yang L, Tong P, Xiao L

International Journal of Nanomedicine 2014, 9:3875-3884

Published Date: 11 August 2014